Abliva AB
π³π΄Norway
- Country
- π³π΄Norway
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.abliva.com
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 180
- Registration Number
- NCT05650229
- Locations
- πΊπΈ
Akron Children's Hospital, Akron, Ohio, United States
πΊπΈThe University of Texas Health Science Center at Houston, Houston, Texas, United States
π§πͺHopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel, Brussel, Belgium
Drug-drug Interaction Study of KL1333 in Healthy Subjects
Phase 1
Completed
- Conditions
- Mitochondrial Disease
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 14
- Registration Number
- NCT04643249
- Locations
- π¬π§
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
Phase 1
Completed
- Conditions
- MELAS SyndromeMitochondrial DiseasesMitochondrial MyopathiesMitochondrial Respiratory Chain Deficiencies
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 72
- Registration Number
- NCT03888716
- Locations
- π¬π§
Covance Leeds, Leeds, West Yorkshire, United Kingdom
π¬π§UCL, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath